Trial Profile
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Unesbulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors PTC Therapeutics
- 06 Dec 2017 Status changed from recruiting to completed.
- 06 Jun 2017 Results (n=31), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Dec 2016 Results (n=18) assessing safety presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics